Ventripoint Diagnostics Valuation

Is VPTD.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VPTD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VPTD.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VPTD.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VPTD.F?

Key metric: As VPTD.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VPTD.F. This is calculated by dividing VPTD.F's market cap by their current book value.
What is VPTD.F's PB Ratio?
PB Ratio	-10.7x
Book	-CA$2.05m
Market Cap	CA$21.05m

VPTD.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	304.4x
Enterprise Value/EBITDA	-4.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does VPTD.F's PB Ratio compare to its peers?

The above table shows the PB ratio for VPTD.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.5x
EKSO Ekso Bionics Holdings	1x	73.0%	US$15.8m
LFWD Lifeward	0.5x	65.0%	US$16.4m
MBOT Microbot Medical	4.4x	n/a	US$15.7m
HLTH Cue Health	0.06x	51.0%	US$14.7m
VPTD.F Ventripoint Diagnostics	n/a	n/a	US$21.0m

Price-To-Book vs Peers: VPTD.F has negative equity and a Price-To-Book Ratio (-10.7x) compared to the peer average (1.5x).

Price to Book Ratio vs Industry

How does VPTD.F's PB Ratio compare vs other companies in the US Medical Equipment Industry?

28 Companies	Price / Book	Estimated Growth	Market Cap
ADGM Adagio Medical Holdings	0.5x	n/a	US$33.14m
MHUA Meihua International Medical Technologies	0.1x	n/a	US$17.92m
RVP Retractable Technologies	0.2x	n/a	US$17.89m
LFWD Lifeward	0.5x	65.0%	US$16.38m

28 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: VPTD.F has negative equity and a Price-To-Book Ratio (-10.7x) compared to the US Medical Equipment industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is VPTD.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VPTD.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-10.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VPTD.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$93.6b

Operates as a health benefits company in the United States.

ELV

US$402.55

0.5%

-15.9%

Lantheus Holdings

US$6.1b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

17.8%

31.5%

electroCore

US$64.0m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

2.5%

101.6%